Whitehawk Therapeutics, Inc. (WHWK) stock
Close on Nov 13, 2026Market cap $174.45MP/E –Yield –
Whitehawk Therapeutics, Inc. saw revenue fall 100.0% to $0 over the twelve months to Sep 30, 2026. Free cash flow was -$73.65M. At the latest close the market valued the company at $174.45M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $174.45M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.07
- Dividend yield
- –
- Free cash flow yield
- -42.22%
Fundamentals
- Revenue
- $0
- Net income
- -$83.29M
- EPS, diluted
- -$0.33
- Free cash flow
- -$73.65M
- Book value per share
- $1.74
- Diluted shares
- 94M
Trading
- Next earnings
- Mar 11, 2027 (estimated, before the open)
- Previous close
- $3.07
- Open
- $3.07
- Day's range
- $2.91 – $3.10
- Volume
- 212,183
- Average volume (20 days)
- 386,472
- Index membership
- Russell 2000 (since Jun 2026)
- Beta (5 years)
- 0.76
- 52-week range
- $1.97 – $5.50
- RSI (14 days)
- 42.3
- Volatility (1 year)
- 69.0%
- Relative volume
- 0.57×
- WACC
- 8.9%
On 1 of our idea list: More cash than they're worth
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | WHWK | S&P 500 | Difference | WHWK per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +1.3% | -3.0% | +4.4 pts | ||
| 3 months | -34.6% | -2.8% | −31.8 pts | ||
| Year to date | +26.4% | +11.5% | +15.0 pts | ||
| 1 year | +46.4% | +13.5% | +32.9 pts | ||
| 3 years | -32.9% | +77.7% | −110.6 pts | -12.5% | +21.1% |
| 5 years | -86.2% | +72.6% | −158.8 pts | -32.7% | +11.5% |
| 10 years | +30500.0% | +308.2% | +30191.8 pts | +77.2% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Whitehawk Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- News
- Update
- Results
- Results
About Whitehawk Therapeutics
Pharmaceutical Preparations
This clinical-stage biopharmaceutical company develops antibody-drug conjugates to treat cancer. Its pipeline features three investigational therapies: HWK-007 for solid tumors such as non-small cell lung and ovarian cancers; HWK-016 for gynecological cancers including ovarian and endometrial; and HWK-206 for small cell lung cancer and neuroendocrine tumors. After divesting its FYARRO business in 2025, the company maintains no active commercial segments. Its pipeline targets adult patients suffering from advanced or metastatic solid tumors refractory to standard therapies.
Company profile, executives and historyWhitehawk Therapeutics stock: common questions
What is Whitehawk Therapeutics's stock price?
WHWK closed at $3.06 on Nov 13, 2026, down 0.33% on the day. Over the past 52 weeks it traded between $1.97 and $5.50.
What is Whitehawk Therapeutics's market cap?
Whitehawk Therapeutics was worth $174.45M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is WHWK's P/E ratio?
Whitehawk Therapeutics lost money over fiscal 2025 (diluted EPS -$0.33), so it has no meaningful P/E ratio.
How much revenue does Whitehawk Therapeutics make?
Whitehawk Therapeutics reported revenue of $0 for the twelve months to Sep 30, 2026, down 100.0% from a year earlier.
Does Whitehawk Therapeutics pay a dividend?
No. Whitehawk Therapeutics has not paid a cash dividend over the last twelve months.
When does Whitehawk Therapeutics report earnings next?
Whitehawk Therapeutics is expected to report Q4 FY2026 results on Mar 11, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has WHWK stock performed over the past year?
Including dividends, WHWK returned +46.4% over the past year, against +13.5% for the S&P 500.
How many WHWK shares are sold short?
2M shares were sold short at the latest FINRA report, 8.71% of the float, or 7.8 days of average trading volume.
Who are Whitehawk Therapeutics's competitors?
Companies most similar to Whitehawk Therapeutics by business, industry and size include CBIO, PYXS, BOLT, IMNM, CTMX.
See a number that looks wrong?